The clinical significance of non-alcoholic fatty pancreatic disease (NAFPD) or fatty pancreas is largely unknown. It is often an incidental finding on abdominal ultrasound, which is not explored further, especially its association with metabolic condition and the risk of pancreatic malignancy. The aim of this study is to evaluate the presence of NAFPD and its associated risk factors among adult medical check-up patients. A large cross-sectional study was done among adult medical check-up patients underwent abdominal ultrasound between January and December 2013 in Medistra Hospital, Jakarta. Data was obtained from the patients’ medical record and include demographic data, blood pressures, fasting blood glucose level, and lipid profile. The presence of fatty pancreas was diagnosed by ultrasound. Bivariate and multivariate analyses were done to find associated risk factors for NAFPD. Statistical analysis was done using SPSS version 17. A total of 1054 cases were included in this study; pancreas cannot be visualized in 153 cases and were excluded from the analysis. Fatty pancreas was present in 315 (35.0 %) patients. Bivariate analyses found associations among fatty pancreas and several risk factors such as gender, age, systolic and diastolic blood pressures, body mass index (BMI), fasting plasma glucose (FPG), triglycerides (TG) and cholesterol levels. Fatty pancreas is a common finding during medical check-up with a prevalence of 35 %. Fatty pancreas has significant association with metabolic factors and it might have an important role in risk of malignancy.

Introduction: Hepatocellular carcinoma (HCC) remains a major cause of cancer-related mortality, and many patients present with intermediate or advanced disease. Transarterial chemoembolization (TACE) is an established treatment; however, its proangiogenic effects support the use of combination therapy. Combinations of TACE with immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) have shown a promising antitumor activity. The objective of this study was to describe post-treatment mRECIST response patterns of TACE alone, TACE plus lenvatinib and pembrolizumab, and TACE plus atezolizumab and bevacizumab for HCC. Methods: This multicentre retrospective, non-randomized pilot study included 25 consecutive patients with unresectable HCC treated with TACE alone (n = 10), TACE–lenvatinib–pembrolizumab (n = 7), or TACE–atezolizumab–bevacizumab (n = 8). The primary outcome was first post-treatment mRECIST response. ORR and DCR were calculated descriptively. Secondary outcomes included imaging interval, TACE exposure, repeat TACE, ALBI change, and OS, estimated using Kaplan–Meier methods. Results: Complete response, partial response, stable disease, and progressive disease occurred in 30.0%, 30.0%, 10.0%, and 30.0% after TACE alone, 14.3%, 28.6%, 57.1%, and 0% after TACE–lenvatinib–pembrolizumab, and 0%, 37.5%, 0%, and 62.5% after TACE–atezolizumab–bevacizumab. ORR/DCR were 60.0%/70.0%, 42.9%/100.0%, and 37.5%/37.5%, respectively. Median imaging intervals were 38.0, 25.0, and 20.0 months. ALBI-grade worsening occurred in 30.0%, 42.9%, and 37.5%; 1-year OS was 78.8%, 83.3%, and 50.0%, respectively. Conclusions: mRECIST response patterns were heterogeneous. Baseline liver-function imbalance, small groups, and non-randomized allocation preclude comparative efficacy inference. Larger prospective studies should standardize treatment sequencing, imaging, liver function assessment, safety monitoring, and survival evaluation.